" class="no-js "lang="en-US"> OriCell Therapeutics - Medtech Alert
Wednesday, July 30, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
OriCell Therapeutics | Pharmtech Focus

OriCell Therapeutics

About OriCell Therapeutics

OriCell Therapeutics
Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Related Story

Fundraising

 Oricell Closes $45M Series B1 Financing to Expand Development of Key Products | MTA

Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

February 28 2023

Oricell Therapeutics, a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, […]

News

 Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology | PTF

Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology

January 31 2023

Oricell Therapeutics, an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, […]

Diseases

 OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology | Pharmtech Focus

OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology

August 2 2022

OriCell Therapeutics (Shanghai) Co., Ltd. (“OriCell” or “the Company”) has announced the completion of Series B […]